IPOs continue to bustle as three more biotechs prepare to make the Nasdaq leap

The biotech IPO market continues to charge full-steam ahead, with three more companies submitting their Nasdaq pitches to the SEC late Friday.

The leaders among the pack are Adagio Therapeutics and Castle Creek Biosciences, each penciling in $100 million initially. Following up the rear is Eliem Therapeutics, jotting down $80 million for its raise estimate less than six months after launching out of RA Capital’s incubator.